×
Viatris Receivables 2010-2025 | VTRS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Viatris receivables for the quarter ending March 31, 2025 were
$3.126B
, a
13.94% decline
year-over-year.
Viatris receivables for 2024 were
$3.221B
, a
12.95% decline
from 2023.
Viatris receivables for 2023 were
$3.7B
, a
2.99% decline
from 2022.
Viatris receivables for 2022 were
$3.815B
, a
10.59% decline
from 2021.
View More
Viatris Receivables 2010-2025 | VTRS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Viatris receivables for 2024 were
$3.221B
, a
12.95% decline
from 2023.
Viatris receivables for 2023 were
$3.7B
, a
2.99% decline
from 2022.
Viatris receivables for 2022 were
$3.815B
, a
10.59% decline
from 2021.
Related Stocks
Company Name
Market
Cap
Danaher (DHR)
$133.5B
Elevance Health (ELV)
$96.1B
CVS Health (CVS)
$84.8B
Cencora (COR)
$55.6B
DiDi Global (DIDIY)
$20.3B
Natera (NTRA)
$20B
BioMerieux (BMXMF)
$15.6B
Solventum (SOLV)
$11.5B
ICON (ICLR)
$11.3B
EUROFINS SCIENT (ERFSF)
$11.1B
Revvity (RVTY)
$11B
CochLear (CHEOY)
$10.9B
Avantor (AVTR)
$10.3B
Doximity (DOCS)
$9.9B
Medpace Holdings (MEDP)
$9B
Sonic Healthcare (SKHHY)
$7.7B
HealthEquity (HQY)
$7.3B
Charles River Laboratories (CRL)
$5.2B
Amplifon S.p.A (AMFPF)
$4.3B
Bausch + Lomb (BLCO)
$4.3B
Alignment Healthcare (ALHC)
$3.5B
Sotera Health (SHC)
$3B
BrightSpring Health Services (BTSG)
$2.9B
Organon (OGN)
$2.9B
Surgery Partners (SGRY)
$2.7B
GeneDx Holdings (WGS)
$2.7B
Concentras Parent (CON)
$2.6B
Progyny (PGNY)
$1.8B
Ardent Health Partners (ARDT)
$1.8B
Premier (PINC)
$1.8B